Voxcan

What Voxcan does

Voxcan is a France-based preclinical Contract Research Organization founded in 2007 and headquartered in L'etoile, operating with 11-50 employees as a specialist in 3D medical imaging services for preclinical studies. The company's imaging capability is integrated within the broader ERBC Group preclinical platform, which delivers GLP and non-GLP scientific services across in vitro and in vivo rodent/non-rodent models, supporting drug discovery, regulatory toxicology, safety pharmacology, laboratory sciences, and non-human primate supply across six European sites with BSL1/BSL2/BSL3 containment and a 6,000+ laboratory footprint. The service portfolio spans discovery (early derisking, ADME/PK/PD/biodistribution, PDX models, imaging), full regulatory toxicology across all regulatory species, safety pharmacology including non-invasive JET technology, and laboratory sciences (bioanalysis, histopathology, digital pathology, GCP-compliant clinical central lab), supplemented by in-silico New Alternative Methods (NAM) for predictive toxicology and pharmacokinetics.

Revenue is generated through fee-for-service preclinical contracts on a quote-based pricing model, with alliance management directors engaging pharmaceutical, biotechnology, chemical, agro-chemical, cosmetic, and medical device clients through tailored proposals. The firm maintains regulatory credentials including GLP, GCP, and full AAALAC accreditation across all sites, with 93% of reports delivered before deadlines and 2,000+ studies performed over the last five years. The go-to-market combines direct enterprise sales with digital channels (Scientist.com marketplace), scientific publications for thought leadership, and active participation at industry congresses (SITOX, SPS, Biospain, European Congress of Toxicologic Pathology).

The most recent strategic developments include a September 2025 strategic partnership with RSSL (Reading Scientific Services Limited) to combine preclinical and analytical capabilities, the launch of the Genesis Discovery Platform bundling discovery services, and the deployment of in-silico NAM capabilities aligned with the regulatory shift away from animal testing. The company operates as part of an integrated European preclinical platform rather than as a standalone imaging boutique, sharing infrastructure, regulatory credentials, and client relationships with the broader ERBC Group service lines.

Name

Voxcan

Legal name

ERBC

Website

https://voxcan.fr

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

11–50 employees

Short description

Voxcan is a French preclinical CRO specializing in 3D medical imaging for drug development, serving pharmaceutical, biotechnology, and chemical industry clients with integrated imaging, toxicology, and regulatory services.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)

akta.pro secondary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Preclinical CRO services
• 3D medical imaging
• Preclinical imaging
• Contract research organization
• Preclinical study imaging

Headquarters

HQ city

L'etoile

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Preclinical Contract Research Services: Fee-for-service preclinical research contracts providing GLP and non-GLP studies across discovery, toxicology, safety pharmacology, laboratory sciences, and NHP supply. Revenue generated through project-based engagements with pharmaceutical, biotechnology, chemical, and consumer product companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Voxcan is a Contract Research Organization that delivers 3D medical imaging services for preclinical studies. The company supports drug and product development sponsors with imaging-based preclinical research capabilities, operating from a single French site with a small specialist team.

Product overview

ERBC is a leading preclinical Contract Research Organization (CRO) offering a comprehensive portfolio of integrated services across drug development. The portfolio comprises Discovery Services (including Genesis, PDX models, and imaging platforms), Regulatory Toxicology, Safety Pharmacology, and Laboratory Sciences (covering bioanalysis, histopathology, digital pathology, and immunology). Key offerings include Safety Assessment for comprehensive toxicology studies, New Alternative Methods (NAM) using in-vitro and in-silico approaches, Clinical Central Lab services for GCP-compliant clinical trials, and NHP Supply for non-human primate breeding and oncology PDX models. Services are delivered through GLP and non-GLP facilities supporting pharmaceutical, biotechnology, chemical, agro-chemical, cosmetic, and medical device industries.

Differentiator

Problem solved

Functional benefit

Products and services

• 3D Medical Imaging Services for Preclinical Studies

Quantifiable outcome

• 93% of reports delivered before deadlines
• +1 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

One partnership is on record.

• RSSL (Reading Scientific Services Limited)coreStrategic or Co-development Partner · 16 September 2025ERBC and RSSL announced a strategic partnership in September 2025 to expand service capabilities and provide comprehensive solutions for drug development clients. RSSL brings additional analytical and consulting expertise to complement ERBC's preclinical service portfolio.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Charles River Laboratories: Global, publicly listed CRO offering preclinical research, safety assessment, and imaging-adjacent services. Comparable as the dominant non-clinical CRO reference point, though far larger and broader than Voxcan.
• Labcorp Drug Development (formerly Covance): Large global CRO with preclinical-to-clinical laboratory services including imaging and safety assessment. Comparable as a broad incumbent competing for the same enterprise pharma outsourcing budgets.
• ICON plc: Major global CRO with preclinical and bioanalytical capabilities. Comparable as a large multi-service incumbent serving pharma and biotech sponsors across geographies.
• WuXi AppTec: Global CRO/CDMO providing preclinical, clinical, and manufacturing services. Comparable as a broad incumbent with preclinical capabilities, though Asia-based and significantly larger.

Direct peers

• Evotec: European-based contract research organization with discovery, preclinical, and translational research services including imaging. Comparable as a mid-sized European CRO with overlapping discovery-to-preclinical scope and similar geographic focus.
• Inotiv: US-based preclinical CRO specializing in safety assessment, toxicology, and research models. Comparable as a preclinical-focused peer with similar service mix, though US-centric.
• Sequani: UK-based preclinical CRO providing safety assessment and regulatory toxicology. Comparable as a Europe-headquartered preclinical CRO of similar scale, competing for similar biotech and pharma sponsors.
• Axis Bio (formerly Axis-Shield): European preclinical CRO offering safety assessment, toxicology, and bioanalytical services. Comparable as a small-to-mid preclinical CRO competing for similar European biotech outsourcing work.
• Celerion: Clinical and preclinical CRO with expertise in early-phase clinical pharmacology, bioanalysis, and translational sciences. Comparable as a peer offering early-stage, science-intensive CRO services.

Emerging players

• Bionova Scientific: Growing preclinical and analytical services provider with imaging-adjacent capabilities. Comparable as a smaller, emerging preclinical services peer that could compete for similar biotech outsourcing budgets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/voxcan

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Voxcan